Surgalign Holdings Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Surgalign Holdings.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.1%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Surgalign Holdings non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:SRGA.Q - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2023	78	-50	-49	-42	N/A
12/31/2022	82	-55	-59	-52	N/A
9/30/2022	83	-62	-64	-56	N/A
6/30/2022	84	-61	-50	-38	N/A
3/31/2022	88	-66	-69	-56	N/A
12/31/2021	91	-81	-66	-52	N/A
9/30/2021	95	-152	-72	-57	N/A
6/30/2021	102	-171	-131	-120	N/A
3/31/2021	98	-185	-120	-109	N/A
12/31/2020	102	-194	-102	-88	N/A
9/30/2020	107	-275	-84	-70	N/A
6/30/2020	108	-266	-27	-11	N/A
3/31/2020	75	-264	-5	13	N/A
12/31/2019	117	-249	-26	-9	N/A
9/30/2019	157	-49	-24	-6	N/A
6/30/2019	197	-29	-23	-5	N/A
3/31/2019	280	-13	-13	3	N/A
12/31/2018	92	-52	3	17	N/A
9/30/2018	280	-14	4	16	N/A
6/30/2018	278	0	-9	1	N/A
3/31/2018	280	3	-22	-9	N/A
12/31/2017	280	3	-9	6	N/A
9/30/2017	280	-1	-13	2	N/A
6/30/2017	280	-22	-3	13	N/A
3/31/2017	275	-22	3	18	N/A
12/31/2016	276	-17	N/A	15	N/A
9/30/2016	278	-3	N/A	17	N/A
6/30/2016	278	4	N/A	15	N/A
3/31/2016	282	10	N/A	14	N/A
12/31/2015	282	12	N/A	9	N/A
9/30/2015	277	8	N/A	8	N/A
6/30/2015	276	7	N/A	14	N/A
3/31/2015	270	6	N/A	11	N/A
12/31/2014	263	0	N/A	7	N/A
9/30/2014	252	-9	N/A	9	N/A
6/30/2014	242	-19	N/A	0	N/A
3/31/2014	218	-24	N/A	0	N/A
12/31/2013	198	-19	N/A	-4	N/A
9/30/2013	182	-8	N/A	-8	N/A
6/30/2013	172	4	N/A	7	N/A
3/31/2013	175	8	N/A	8	N/A
12/31/2012	178	8	N/A	21	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista SRGA.Q è superiore al tasso di risparmio ( 2.2% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di SRGA.Q cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di SRGA.Q cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di SRGA.Q cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di SRGA.Q cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di SRGA.Q è previsto essere elevato tra 3 anni

Surgalign Holdings Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

Consensus revenue estimates fall by 38%

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Price target decreased to US$11.00

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)

Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System

Surgalign Holdings, Inc. (NasdaqGS:SRGA) acquired Medical Device Prototyping and Manufacturing Facility in San Diego.

Independent Director has left the company

VP, Chief Accounting Officer & Corporate Controller has left the company

Full year 2020 earnings released: US$2.61 loss per share (vs US$2.91 loss in FY 2019)

Surgalign Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020

Shirley Weis Not to Stand for Re-Election as Director of Surgalign Holdings, Inc. At 2021 Annual Meeting of Stockholders

Have Insiders Been Buying Surgalign Holdings, Inc. (NASDAQ:SRGA) Shares?

Price target lowered to US$5.00

Surgalign Holdings, Inc. to Report Q4, 2020 Results on Mar 11, 2021